Hims & Hers agrees to stop selling compounded Wegovy and Ozempic, switching to branded versions by March 2026, ending a patent lawsuit with Novo Nordisk.

Hims & Hers and Novo Nordisk have settled their patent lawsuit, ending legal conflict over Hims’ sale of compounded versions of Wegovy and Ozempic. Under the agreement, Hims will stop promoting and selling compounded GLP-1 drugs and will instead offer branded versions of Wegovy and Ozempic through its telehealth platform starting in March 2026. The FDA’s threat to restrict ingredients used in compounding contributed to the resolution. Novo Nordisk dropped its lawsuit but reserves the right to refile. Hims & Hers shares rose over 36% on the news, while Novo Nordisk’s stock increased 1.8%.